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 Myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) is an unexplained incapacitating illness that may
affect up to 4 million people in the United States alone. There are no validated laboratory tests for diagnosis or
management despite global efforts to find biomarkers of disease. We considered the possibility that inability to
identify such biomarkers reflected variations in diagnostic criteria and laboratory methods as well as the timing
of sample collection during the course of the illness. Accordingly, we leveraged two large, multicenter cohort studies
of ME/CFS to assess the relationship of immune signatures with diagnosis, illness duration, and other clinical varia-
bles. Controls were frequency-matched on key variables known to affect immune status, including season of
sampling and geographic site, in addition to age and sex. We report here distinct alterations in plasma immune
signatures early in the course of ME/CFS (n = 52) relative to healthy controls (n = 348) that are not present in
subjects with longer duration of illness (n = 246). Analyses based on disease duration revealed that early ME/CFS cases
had a prominent activation of both pro- and anti-inflammatory cytokines as well as dissociation of intercytokine
regulatory networks. We found a stronger correlation of cytokine alterations with illness duration than with mea-
sures of illness severity, suggesting that the immunopathology of ME/CFS is not static. These findings have critical
implications for discovery of interventional strategies and early diagnosis of ME/CFS.d
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Myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) is a dis-
abling disorder with complex features that can include fatigue, mem-
ory and concentration deficits, sleep disturbances, headache, joint and
muscle pain, postexertional malaise, and gastrointestinal and immune
system dysfunction (1–5), lasting for 6 months or more. Elderly patients
with ME/CFS are at increased risk for non-Hodgkin’s lymphoma (6).
The diagnosis of ME/CFS is largely based on recognition of signs and
symptoms by experienced clinicians (1). Although laboratory assays
play a role in the diagnostic process, they are used to rule out other con-
ditions that can mimic aspects of ME/CFS, rather than as biomarkers
to facilitate early diagnosis. Efforts to identify immune biomarkers in
ME/CFS have produced inconsistent results (1, 7–9). Inconsistencies
may reflect variations in the use of diagnostic criteria or laboratory
methods as well as the timing of sample collection during the course
of the illness (10).
To better control for heterogeneity across patients and sampling
strategies, in the present study we leveraged the clinical databases and
biological specimen repositories of two recent, large, multicenter cohort
studies of ME/CFS to assess the relationship of immune signatures (51
cytokines) with diagnosis and other clinical variables: (i) the National
Institutes of Health (NIH) study, initially developed to address a specific1Center for Infection and Immunity, Columbia University Mailman School of Public Health,
New York, NY 10032, USA. 2Department of Epidemiology, Columbia University Mailman
School of Public Health, New York, NY 10032, USA. 3Stanford University, Palo Alto, CA
94305, USA. 4Institute for Neuro-Immune Medicine, College of Osteopathic Medicine,
Nova Southeastern University, Fort Lauderdale, FL 33314, USA, and Miami VA Medical
Center, Miami, FL 33125, USA. 5Levine Clinic, New York, NY 10021, USA. 6Massachusetts
General Hospital, Harvard Medical School, Boston, MA 02114, USA. 7Fatigue Consultation
Clinic, Salt Lake City, UT 84102, USA. 8Sierra Internal Medicine at Incline Village, Incline
Village, NV 89451, USA. 9Harvard Medical School, Brigham and Women’s Hospital, Boston,
MA 02115, USA. 10Departments of Neurology and Pathology, College of Physicians and
Surgeons, Columbia University, New York, NY 10032, USA.
*Corresponding author. E-mail: mh2092@cumc.columbia.edu
Hornig et al. Sci. Adv. 2015;1:e1400121 27 February 2015hypothesis regarding infectious exposure (11) and (ii) the Chronic Fatigue
Initiative (CFI) cohort study (12). Controls were frequency-matched
on key variables known to affect immune status, including season of
sampling and geographic site, in addition to age and sex. We investi-
gated the relationship of diagnosis and clinical phenotype to immune
profiles derived from plasma samples collected at the same time of day
under controlled conditions of a mild stressor (defined as completion
of study forms and procedures for the ME/CFS study population) (13).RESULTS
Table 1 shows the demographic features of the study group, including
52 subjects with short-duration illness (≤3 years), 246 subjects with
long-duration illness (>3 years) (total of 298 cases), and 348 controls.
For ME/CFS cases participating in both the NIH and the CFI cohort
studies, only the clinical and laboratory data obtained during partici-
pation in the earlier NIH study were included in the analyses (the num-
ber of control subjects is greater than that of cases because the NIH
and CFI control groups have no overlap). As anticipated, subjects with
more recent onset of illness were younger (40.5 ± 13.6 years) thanME/CFS
cases with a long duration of illness (50.2 ± 11.4 years, in comparison with
the short-duration group, P < 0.0001) as well as in comparison to controls
(48.5 ± 12.0 years, P < 0.0001). Multidimensional Fatigue Inventory
(MFI) mental fatigue subscale scores in the short- and long-duration
ME/CFS groups were, as expected, both higher than in the control group
(P < 0.0001), but did not differ significantly from each other.
Cases versus controls
General linear model (GLM) and t-test follow-up comparison of all
ME/CFS cases (short and long duration combined, n = 298) with
controls (n = 348) yielded few significant results, with cases showing
lower levels for most analytes (tables S1 to S3). Cases had lower1 of 10
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 plasma levels of the proinflammatory cytokines interleukin (IL)-
17A (pg/ml, mean ± SEM; cases: 18.3 ± 0.6; controls: 20.6 ± 0.6; P =
0.0043), CXCL8 (IL-8) (cases: 3.4 ± 0.2; controls: 4.0 ± 0.2; P = 0.0437),
CXCL10 [interferon-inducible protein-10 (IP-10)] (cases: 40.5 ± 0.8;
controls: 43.5 ± 1.2; P = 0.0444), tumor necrosis factor–b (TNFb) (cases:
2.4 ± 0.2; controls: 3.3 ± 0.2; P = 0.0028), soluble Fas ligand (sFasL) (cases:
10.2 ± 0.3; controls: 11.4 ± 0.3; P = 0.0129), and IL-6 (cases: 10.2 ±
0.4; controls: 10.9 ± 0.3; P = 0.0401), as well as of the anti-inflammatory
cytokine IL-10 (cases: 6.8 ± 0.2; controls: 7.2 ± 0.2; P = 0.0241) and
CSF1 [macrophage colony-stimulating factor (M-CSF)], a factor asso-
ciated with the immunosuppressive M2 phenotype of macrophages/
microglia (14) (cases: 7.1 ± 0.3; controls: 7.9 ± 0.3; P = 0.0235).
In contrast, the adipose-derived cytokine, leptin, was increased in
the larger ME/CFS case group (short and long duration combined)
as compared to controls (cases: 1506.4 ± 76.4; controls: 1398.4 ± 96.3;
P = 0.0301).Hornig et al. Sci. Adv. 2015;1:e1400121 27 February 2015Short-duration versus long-duration ME/CFS versus controls
GLM comparison of short-duration ME/CFS cases (≤3 years, n = 52),
long-duration ME/CFS cases (>3 years, n = 246), and controls (n = 348)
(with and without sex and age included in the models) showed signif-
icant differences for more than half of the 51 cytokines (tables S4 to S6).
Follow-up t tests showed that short illness duration subjects generally
had higher cytokine levels than controls or long-duration cases. Both
classical proinflammatory cytokines {short duration versus control:
IL-1a, P = 0.0178; CXCL8 (IL-8), P = 0.0112; IL-12p40, P = 0.0009;
IL-17A, P = 0.0243; TNFa, P = 0.0261; TRAIL [TNF-related apoptosis-
inducing ligand (TNFSF10)], P = 0.0079; CC chemokine ligand (CCL)-2
[monocyte chemoattractant protein 1 (MCP1)], P = 0.0208; stem cell
factor (SCF) [steel factor (SF)], P = 0.0110; resistin, P = 0.0024} and
anti-inflammatory cytokines [short duration versus control: IL-1 recep-
tor antagonist (IL-1RA), P = 0.0105; IL-4, P = 0.0028; IL-13, P = 0.0198]













versus controlP* PSex, n (%) 0.80 0.95Female 220 (73.8) 39 (75.0) 181 (73.6) 260 (74.7)Male 78 (26.2) 13 (25.0) 65 (26.4) 88 (25.3)Age [mean (SD)] 48.5 (12.4) 40.5 (13.6) 50.2 (11.4) 48.5 (12.0) 0.95 <0.0001†Illness duration, years [mean (SD)] 13.2 (9.2) 1.7 (0.8) 15.6 (8.2) —MFI mental fatigue subscale score [mean (SD)] 15.3 (3.6) 15.2 (3.7) 15.3 (3.6)‡ 6.2 (2.7)§ <0.0001 <0.0001¶Race, n (%) 0.54 0.77White 292 (98.0) 52 (100.0) 240 (97.6) 337 (96.8)African American 1 (0.3) 0 (0.0) 1 (0.4) 5 (1.4)Asian 3 (1.0) 0 (0.0) 3 (1.2) 4 (1.1)Other 2 (0.7) 0 (0.0) 2 (0.8) 2 (0.6)Site, n (%) 0.80 0.22Boston, MA 54 (18.1) 4 (7.7) 50 (20.3) 55 (15.8)Miami, FL 57 (19.1) 9 (17.3) 48 (19.5) 67 (19.3)New York, NY 67 (22.5) 15 (28.8) 52 (21.1) 72 (20.7)Palo Alto, CA 23 (7.7) 1 (1.9) 22 (8.9) 23 (6.6)Salt Lake City, UT 46 (15.4) 11 (21.2) 35 (14.2) 65 (18.7)Sierra, NV 51 (17.1) 12 (23.1) 39 (15.9) 66 (19.0)Months of sample acquisition, n (%)|| 0.02 <0.0001**January to March 77 (25.9) 11 (21.2) 66 (26.9) 95 (27.3)April to June 72 (24.2) 17 (32.7) 55 (22.4) 90 (25.9)July to September 26 (8.8) 11 (21.2) 15 (6.1) 53 (15.2)October to December 122 (41.1) 13 (25.0) 109 (44.5) 110 (31.6)*Sex, race, site, and months of sample acquisition, c2 test; age and MFI, Kruskal-Wallis test (three-group comparisons) and Mann-Whitney U tests (two-group comparisons). †Significant
intergroup comparisons for age: short versus long duration and short duration versus control, both P < 0.0001. ‡n = 238 (MFI scores missing for 8 long-duration subjects). §n = 341 (MFI
scores missing for 7 control subjects). ¶Significant intergroup comparisons for MFI subscale: short duration versus control and long duration versus control, both P < 0.0001. ||Blood
draw date missing for one ME/CFS case. **Significant intergroup comparisons for months of sample acquisition: short versus long duration, P = 0.001.2 of 10
R E S EARCH ART I C L E
 o
n






 shown in Fig. 1; all means, SEM, and t-test
data are in table S6). In contrast, only 2 of
the 51 cytokines were reduced in short-
duration subjects as compared with con-
trols: CD40 ligand (CD40L) (P = 0.0037) and
platelet-derived growth factor BB (PDGFBB)
(P = 0.0004).
Similar patterns were obtained when
comparing short-duration with long-duration
subjects. For cytokines that differed between
short- and long-duration groups, levels were
correlated with duration of illness, and in
the expected direction: inverse correlations
with duration of illness for cytokines that
were increased in the short-duration group,
and positive correlations for the two cyto-
kines with reduced levels in the short-
duration group (CD40L and PDGFBB)
(table S7). For this same set of cytokines,
when long-duration subjects were compared
to healthy controls, we observed the oppo-
site pattern to that observed when short-
duration cases were compared to controls:
the same cytokines that were higher than
controls in short-duration cases were lower
than controls in long-duration cases, except
for levels of CD40L and PDGFBB, which
were increased (table S6). The inclusion of
the MFI mental fatigue subscale score to
GLM analyses as an additional continuous
covariate did not change these results (data
not shown).




After feature selection procedures, cyto-
kines and predictor variables meeting ei-
ther the LASSO (least absolute shrinkage
and selection operator) or principal com-
ponents analysis (PCA)/partial least square
(PLS) criteria (table S8) were selected for
inclusion in a final logistic regression model
with short- versus long-duration ME/CFS
as the outcome. Younger age was asso-
ciated with short-duration ME/CFS sub-
group status, as anticipated [odds ratio (OR),
0.953; 95% confidence interval (CI), 0.926
to 0.981; P = 0.001].
Two proinflammatory cytokines had a
prominent association with short-duration
ME/CFS (Table 2). This association was
markedly elevated for interferon-g (IFNg),
with an OR of 104.77 (95% CI, 6.975 to
1574.021; P = 0.001), and more modestly
elevated for IL-12p40 (OR, 1.501; 95% CI,
1.075 to 2.096; P = 0.017). Short-durationHornig et al. Sci. Adv. 2015;1:e1400121 27 FebruaFig. 1. Comparison of plasma cytokine levels
in short-duration ME/CFS, long-duration ME/CFS,
and control subjects. (A) Proinflammatory cy-
tokines. (B) Anti-inflammatory cytokines. The
means ± SEM for each cytokine are shown. Only
cytokines meeting significance criteria (P < 0.05)
in either the one-way or the two-way GLM are
represented. *P < 0.05, **P < 0.01, ***P < 0.001,
****P < 0.0001 by two-sample t-test comparisons.ry 2015 3 of 10
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 subgroup status was also associated with lower plasma levels of TNFa
(OR, 0.866; 95% CI, 0.765 to 0.980; P = 0.023), CSF2 [granulocyte-
macrophage colony-stimulating factor (GM-CSF)] (OR, 0.970; 95%
CI, 0.947 to 0.995; P = 0.017), and IL-12p70 (OR, 0.783; 95% CI,
0.650 to 0.942; P = 0.010).
Network associations
Network diagrams of intercytokine correlations revealed unusual reg-
ulatory relationships among cytokines in the short-duration ME/CFS
group that were not apparent in either the long-duration case group
or healthy controls (Fig. 2). Whereas CD40L drove most of the inverse
relationships with other immune molecules in long-duration ME/CFS
and controls, CD40L was only related to five other cytokines in the
short-duration ME/CFS group; furthermore, only one of these associa-
tions, PDGFBB, was negative. PDGFBB was a negative driver of many
other cytokines in long-duration ME/CFS subjects and healthy
controls, but had no inverse associations with other cytokines within
the short-duration subset. Among short-duration subjects, the levels of
the adipose-related cytokine leptin were only correlated with IL-12p40,
CSF2 (GM-CSF), and serpin E1 [plasminogen activator inhibitor-1 (PAI1)],
whereas leptin was tightly related to most of the other 51 cytokines in
both the long-duration ME/CFS and the control groups. Leptin also had
an inverse relationship to PDGFBB among controls.
CART analysis
The CART (Classification and Regression Tree) decision tree machine
learning method was applied to plasma cytokine and clinical covariate
data to find predictors that distinguished ME/CFS cases of short illness
duration (≤3 years) from those with a long illness duration (>3 years).
Predictor variables and cutoffs at each node in the decision tree are
those with the maximum capacity to differentiate between the differ-
ent levels of the dependent variable (here, the diagnostic subgroups of
short-duration versus long-duration ME/CFS cases). Resulting cyto-Hornig et al. Sci. Adv. 2015;1:e1400121 27 February 2015kine classifiers are dependent on subject age within both the short-
duration and long-duration ME/CFS subgroups, but predictor patterns
varied differently with age across different cytokines (Fig. 3). Results
show that cytokine differences are not solely due to older mean age
of the long-duration ME/CFS subgroup.
Among subjects between 25.4 and 56.7 years of age, short-duration
subjects were more likely than long-duration subjects to have higher
plasma levels of IL-12p40 (>6.39 pg/ml) in association with lower
levels of CCL11 (eotaxin; <36.36 pg/ml), IL-1RA (<37.58 pg/ml),
and IL-1a (<5.37 pg/ml). When restricting to short-duration subjects
between 29.3 and 56.7 years of age, the short-duration group was best
distinguished from the long-duration group by the combination of
elevated IL-12p40 (≥6.39 pg/ml), IL-1RA (≥37.58 pg/ml), and
transforming growth factor–a (TGFa) (≥2.3 pg/ml) along with lower
levels of CCL11 (<36.36 pg/ml) and resistin (<514 pg/ml).
Cytokine predictors of long-duration ME/CFS status also varied
with age. Low levels of IL-17F (<0.54 pg/ml) were characteristic only
of younger long-duration subjects (<25.4 years of age). Among sub-
jects >25.4 years, two subsets of long-duration ME/CFS cases were ap-
parent: one distinguished by lower levels of IL-12p40 (<6.39 pg/ml)
and another subgroup of long-duration cases who had higher levels
of IL-12p40 (>6.39 pg/ml) in combination with higher CCL11 levels
(≥36.36 pg/ml).DISCUSSION
This is the first study to demonstrate altered plasma immune signa-
tures early in the course of ME/CFS that are not present in subjects
with longer duration of illness. No substantive differences were found
between cases and controls when short- and long-duration cases were
combined and compared with healthy control subjects. However,
analyses that considered duration of illness revealed that early ME/CFS
cases had a prominent activation of both pro- and anti-inflammatory
cytokines as well as a dissociation of characteristic intercytokine reg-
ulatory networks. Previous studies of immune disturbances in ME/CFS
may have missed these findings because they were collected from het-
erogeneous study populations, without characterization of the duration
of illness. We found a stronger correlation of cytokine alterations with
duration of illness than with global measures of severity of illness, sug-
gesting that the immunopathology of ME/CFS is not static.
The marked association of IFNg with the early phase of illness that
was detected through logistic regression modeling is consistent with a
viral trigger or disrupted immune regulatory networks. IFNg is a product
of activated T cells [particularly CD8+ and CD4+ T helper 1 (TH1) cells],
natural killer cells, as well as activated macrophages in the periphery
(15, 16) and microglia in the central nervous system (17–19). IFNg
may disrupt immune cell homeostasis, resulting in a TH2-type skew
and greater vulnerability toward the development of certain types of
autoimmune responses (20–23). Some studies in ME/CFS (7), but not
all (24–26), have found plasma levels of IFNg to be elevated, with
effects restricted to males in one study (27). Postviral fatigue in West
Nile virus infection has also been reported to be associated with ele-
vations of IFNg (28). Individuals experiencing more severe fatigue
as part of an acute sickness response to infection have been noted
to have specific genetic polymorphisms in IFNG (29). IFNg may ac-
celerate degradation of tryptophan, resulting in depletion of the neu-
rotransmitters serotonin and melatonin in the central nervous systemTable 2. Final logistic regression model for association of plasma
cytokines and covariates with short-duration versus long-duration
ME/CFS. Final model includes cytokines meeting LASSO and/or PCA/PLS
criteria (see Materials and Methods and Supplementary Materials and
Methods). Bold text indicates P values <0.05.Variable OR 95% CI PAge 0.953 0.926–0.981 0.001Sex 0.669 0.296–1.512 0.334IL-12p40 1.501 1.075–2.096 0.017IL-12p70 0.783 0.650–0.942 0.010IL-17A 0.988 0.866–1.127 0.857IFNg 104.777 6.975–1574.021 0.001TNFa (TNFSF2) 0.866 0.765–0.980 0.023sFasL 0.981 0.856–1.126 0.789CCL11 (eotaxin) 0.966 0.929–1.004 0.075CSF1 (M-CSF) 1.068 0.901–1.267 0.448CSF2 (GM-CSF) 0.970 0.947–0.995 0.017PDGFBB 0.998 0.994–1.002 0.3704 of 10
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 through activation of indoleamine-
2,3-dioxygenase, a rate-limiting enzyme
in the kynurenine pathway. Activa-
tion of this pathway also results in
increased levels of quinolinic acid, a
neurotoxic compound that acts as
an agonist at glutamatergic [NMDA
(N-methyl-D-aspartate)] receptors (30–32).
Psychomotor changes, including cog-
nitive problems (deficits of memory
and attention) as well as affective dis-
turbances, are correlated with changes
in the kynurenine pathway in disor-
ders ranging from Alzheimer’s disease
(33) to major depression (34). We hy-
pothesize that IFNg-mediated lesions
in kynurenine metabolismmay culmi-
nate in the depression and psycho-
motor retardation that contribute to
disability in some patients withME/CFS
(34–36).
Our observation that the levels of
CD40L were both decreased and dis-
sociated from normal intercytokine
regulation early in the course of ill-
ness in ME/CFS is intriguing. CD40L
(CD154), a TNF superfamily trans-
membrane protein found on immune
(especially CD4+ T cells), endothelial,
and smooth muscle cells, is essential
for regulation of B cell maturation
and isotype switching (37); however,
abnormally high levels have been as-
sociated in some studies with risk of
adverse neurovascular events (38) as
well as mild cognitive impairment (39)
and Alzheimer’s disease (40). Of poten-
tial relevance for ME/CFS, constitutive
CD40L deficiency (X-linked hyper-
immunoglobulin M syndrome) not
only is associated with susceptibility
to recurrent infections of the sinuses
and pulmonary tracts but also can
present with a pattern of cognitive and
neurologic decline that is unexplained
by the presence of any known pathogen
or clear clinical signs of encephalitis
(41). Additional immunophenotyping
studies, including isotype analyses and
in vitro studies comparing peripheral
blood mononuclear cells from short-
and long-duration subjects, may also
reveal immune signaling pathway differ-
ences early in the course of illness that
may bemore amenable to modification
and help clarify this pattern of results.
We were surprised to find that
the levels of so many cytokines wereA Inverse correlations 
CD40L IL-12p40 
Inverse correlations 
CD40L IL-1β, IL-4, IL-6, IL-10, IL-12p40, IL-17A, 
TNFα, TNFβ, sFasL, TRAIL, CCL2, 
CCL3, CXCL8, TGFα, CSF1, SCF, 
resistin, sICAM-1, VCAM-1 
PDGFBB IL-12p40, IL-17A, TNFβ, sFasL, CCL3, 
CCL5, CXCL8, CSF1, resistin 
CCL5 LIF, PDGFBB 
IL6 CCL11 
NGF resistin, VCAM-1 
VCAM1 CD40L, βNGF 
B 
C Inverse correlations 
CD40L IL-1α, IL-1β, IL-4, IL-6, IL-10, IL-12p40, 
IL-12p70, IL-13, IL-17A, TNFα, TNFβ, 
sFasL, TRAIL, IFNα2, CCL3, CCL5, 
CXCL8, TGFα, CSF1, SCF, resistin 
PDGFBB IL12p40, TNFβ, sFasL, IFNα2, CCL5, 
leptin, resistin, sICAM1, VCAM1 
CCL5 IL-5, IL-6, IL-12p70, IL-13, IFNα2, TGFβ, 
LIF, PDGFBB 
IL6 CD40L, CCL5, VCAM-1 
LIF CCL5, sICAM-1, VCAM-1 
NGF VCAM-1 
TGF  CCL5, IL-12p40, VCAM-1 
sICAM1 IFNα2, LIF 
VCAM1 IL-2, IL-5, IL-6, IL-12p70, IL-13, IFNα2, 




Fig. 2. Network cytokine-cytokine associations differ for short-duration versus long-duration ME/CFS
versus control subjects. (A to C) Network diagrams for short-duration ME/CFS subjects (A, n = 52), long-
duration ME/CFS subjects (B, n = 246), and healthy controls (C, n = 348). Network diagrams of the 51
measured cytokines were created in NodeXL (http://nodexl.codeplex.com) using a 0.01 family-wise false dis-
covery rate (FDR) to adjust for multiple comparisons (A, short-duration group, P = 0.0065; B, long-duration
group, P = 0.0081; C, control group, P = 0.0075). Red lines (edges) indicate negative correlations, and gray
lines indicate positive cytokine-cytokine correlations with associated P values that fall below the corrected P
value criterion for each group. Note that whereas CD40L drives most of the inverse relationships with other
immune molecules in both the long-duration ME/CFS and the control groups, CD40L is only related to five
other cytokines in the short-duration ME/CFS group, and only one of these associations is negative (inverse
relationship with IL-12p40). Similarly, PDGFBB is a negative driver of many other cytokines in both long-duration
ME/CFS and control subjects, but shows no negative correlations with other cytokines in the short-duration subset.5 of 10
R E S EARCH ART I C L E
 o
n






 higher in short-duration cases than in healthy controls. Equally
surprising was the observation that these same cytokines were lower
in long-duration cases than in healthy controls. We can only speculate
as to why that might be. Possibly, as occurs with pancreatic b cell
production of insulin in type 2 diabetes (42), or in chronic infections
(43), the exuberant stimulation of cytokine-producing cells seen in
the first 3 years of the illness leads to an “exhaustion” of the cytokine-
producing cells thereafter. Although CD57, a marker of premature
immune senescence that is found to increase in later phases of some
chronic viral infections such as HIV (44) or hepatitis C virus (HCV)
(45), has been shown to be decreased in previous work in ME/CFS
(46, 47), studies that control for duration of illness may provide ad-
ditional clarity as to the potential contribution of mechanisms of im-
mune exhaustion to the immune changes observed later in the course
of ME/CFS.Hornig et al. Sci. Adv. 2015;1:e1400121 27 February 2015As anticipated, longer-duration ME/CFS subjects were significantly
older than those presenting closer to the onset of their illness (short-
duration subjects, ≤3 years). However, age was only associated with a
handful of cytokines in our GLM analyses (table S2). In addition,
CART analysis (Fig. 3) revealed the presence of age-dependent cyto-
kine subgroups within the short- and long-duration ME/CFS sub-
groups, demonstrating that the predictive value of cytokine levels
was not linearly associated with age. Future longitudinal study designs
should control for effects of both age and illness severity within sub-
jects to better define potential interactions of aging and the disease
process in this patient population. Given the evidence of a sharply in-
creased risk of non-Hodgkin’s lymphoma in elderly subjects with
ME/CFS (6), it is of paramount importance to understand the clinical
significance of age- and illness-related changes in immune system func-
tion in this vulnerable population.
We found significantly different levels of CD40L in the short-
duration versus long-duration subgroups, and an uncoupling of
CD40L levels with other cytokines in the short-duration subgroup.
To our knowledge, only one other study has evaluated CD40L levels
in patients with ME/CFS and found low levels (as did we, in the short-
duration patients) (48). CD40L plays an important role in B cell mat-
uration (49). There is indirect evidence that B cells play an important
role in ME/CFS (50), although not all studies have found abnormal-
ities of B cell phenotype or function (51, 52). Most studies indicate a
higher frequency of autoantibodies in the illness (53), and a random-
ized trial of a monoclonal antibody that targets B cells has demon-
strated symptom improvement in some patients (54).
Our study has limitations. First, our strategy was to measure a large
panel of cytokines with the rationale that findings might rapidly
transition to clinical diagnostic applications. We did not pursue pro-
teomic discovery with the goal of identifying noncytokine biomarkers.
Second, the CART analysis was conducted on a training set (the entire
study sample) but not then validated on an independent test set.
Third, our assays were conducted using only blood samples. Although
blood is more easily obtained than cerebrospinal fluid, analysis of
the latter may enable unique insights into immune activation in the
central nervous system. This is important because many signs and
symptoms of ME/CFS are consistent with central nervous system dys-
function (55).
The presence of a specific immune profile early in the course of
ME/CFS has important implications for the diagnostic process. First,
we were able to define a distinctive immune signature that differed
from that of healthy controls. Integration of these immune markers
with clinical findings will provide clinicians with a stronger framework
for establishing an ME/CFS diagnosis, and, possibly, make it easier to
rule out other conditions at an earlier time point. It may also facilitate
resolution of some of the clinical heterogeneity observed in this illness
(56) by enhancing the ability to distinguish cytokine-associated phe-
notypes from ME/CFS subsets wherein disease may be triggered by
nonimmunologic factors. Second, the restriction of this pattern of im-
mune disturbances to short-duration as opposed to long-duration
cases suggests that both the dysregulation of immune cell interactions
(for example, faulty CD40L signaling leading to impaired T and B cell
interactions) and the opportunities for intervention may be transient.
Therapeutic strategies that specifically target abnormalities found in
these early immune profiles may present novel but time-limited op-
portunities not only for remediation but potentially also for staving off
the long-term, chronic decline associated with ME/CFS. ProspectiveFig. 3. CART analysis of cytokine and clinical predictors in subjects
with short- and long-duration ME/CFS. The CART decision tree machine
learning method was applied to plasma cytokine and clinical covariate data
to derive predictors associated with ME/CFS of short (≤3 years, n = 52) ver-
sus long (>3 years, n = 246) duration. Predictor variables and cutoffs at
each of the nodes in the decision tree are those with the maximum capac-
ity to differentiate between the different levels of the dependent variable
(here, short versus long duration of illness). Resulting cytokine classifiers are
highly dependent on subject age within both the short-duration and long-
duration ME/CFS subgroups, but predictor patterns are shown to vary dif-
ferently with age across different cytokines. These data provide evidence
that cytokine differences are not solely due to the older mean age of the
long-duration ME/CFS subgroup.6 of 10
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stage and follow the trajectory of immune responses over the course of
illness are required to elucidate the clinical significance of these find-
ings. Delineation of immune profiles in well-characterized subjects
with ME/CFS, both early and late in the course of illness, as we have
presented here, provides a unique tool for the establishment of clini-
cally relevant phenotypes and discovery of novel treatment targets. If
replicated in longitudinal studies, these data may provide a basis for
early immunomodulatory intervention to prevent long-term, recalci-
trant illness. o
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 MATERIALS AND METHODS
Experimental design
Study population. Cases and controls were derived from two
large studies of ME/CFS in the United States: a study supported by
the National Institute of Allergy and Infectious Diseases (NIAID) of
the NIH (cases, n = 147; controls, n = 146) (11) and another sup-
ported by the CFI (cases, n = 203; controls, n = 202) (12). Although
inclusion/exclusion criteria varied slightly for the two studies (see be-
low), both required subjects to have previously been diagnosed with
ME/CFS at one of the participating clinical sites across the United
States (five of six sites participating in the NIH study also participated
in the CFI study) to be eligible. Up to 25% of the cases who partici-
pated in the NIH study were re-recruited about 1 year later for the CFI
study; for these cases (n = 52), clinical and laboratory data from the
earlier NIH study were retained in the final, combined data set. None
of the control subjects participating in the NIH study were re-recruited
for the CFI study; thus, all control data were included in the current
analysis. In both studies, controls were frequency-matched on sex, age
(±5 years), race/ethnicity, geographic region of residence, and season
of case subject blood sampling (±12 weeks). All participants com-
pleted screening and assessment instruments, underwent a standard-
ized physical examination, and provided blood samples (11). A
diagnosis of ME/CFS requires duration of illness for more than 6 months;
hence, acute disease cannot be appreciated except in retrospect. A
3-year cutoff for early ME/CFS cases was used on the basis of feasi-
bility of recruitment and longitudinal changes in immune profiles in
persistent infections with West Nile virus, HCV, and HIV (28, 57–61).
Illness onset was defined as the date when a patient reported the onset
of the clinical features that led to a later diagnosis of ME/CFS illness,
rather than the date when a physician made the diagnosis of ME/CFS.
Discrepancies were resolved by clinician consensus ratings after review
of all available data. Severity of illness scores were based on the mental
fatigue subscale of the MFI (62). In all, the study included 298 cases of
ME/CFS and 348 matched healthy control subjects.
NIH study case definition. NIH cases were between the ages of 18
and 70 years and met both the 1994 CDC Fukuda criteria (63) and the
2003 Canadian consensus criteria for ME/CFS (2), expanded in 2010
(3). Additionally, all NIH study cases had a history of a viral-like pro-
drome before the onset of CFS and reduced functional status in two or
more areas identified by the RAND36 survey (11).
CFI cohort study case definition. CFI cohort cases were between
the ages of 18 and 65 years and met either or both of the 1994 CDC
Fukuda criteria (63) and the 2003 Canadian consensus criteria for
ME/CFS (2). Twenty-five percent of all CFI cohort study cases were
re-recruited from the NIH study.Hornig et al. Sci. Adv. 2015;1:e1400121 27 February 2015Informed consent. All participants provided informed, written con-
sent in accordance with protocols approved by the Institutional Review
Board (IRB) for research with human subjects associated with each refer-
ring institution: (a) NIH study—Columbia University (included approvals
for work at clinical sites not associated with an IRB), Stanford University,
and Brigham and Women’s Hospital (Partners Healthcare IRB), and (b)
CFI study—Columbia University, Western IRB (clinical sites not asso-
ciated with an IRB), and Massachusetts General Hospital (Partners
Healthcare IRB). Only those NIH study subjects who provided written
consent to be recontacted were re-recruited for the CFI study.
Biologic samples. Blood samples were obtained from consented
subjects immediately after clinical assessments were complete in an
effort to simulate a mild stressor. To minimize variation associated with
circadian rhythms (64, 65), samples were collected between the hours
of 10 a.m. and 2 p.m. Samples were deidentified and shipped over-
night at 2° to 4°C for processing at either Columbia University (NIH
study) or the CFI Biobank at Duke University (CFI study). Plasma
aliquots were then frozen at −80°C until use in immunoassays to avoid
additional freeze/thaw cycles. For subjects participating in both the
NIH and the CFI cohort studies (n = 52 ME/CFS subjects), only the
NIH plasma samples and their associated clinical assessment data
were included in the analysis.
Cytokine analyses. The plasma concentrations of the following
immune molecules were determined using a magnetic bead–based
51-plex immunoassay: IL-1 superfamily—IL-1a, IL-1b, IL-1RA; type
I IL/g chain family—IL-2, IL-4, IL-7, IL-13, IL-15; type I IL/b chain
family—IL-5, GM-CSF (CSF2); IL-6 (gp130) family—IL-6, LIF; IL-12
family—IL-12p40, IL-12p70; IL-10 family—IL-10; IL-17 family—IL-17A,
IL-17F; type I IFNs—IFNa2, IFNb; type II IFN—IFNg; TNF
superfamily—TNFa (TNFSF2), TNFb (TNFSF1), CD40L, sFasL
(TNFSF6), TRAIL (TNFSF10); CC chemokines—CCL2 (MCP1), CCL3
[macrophage inflammatory protein-1a (MIP-1a)], CCL4 (MIP-1b),
CCL5 [regulated on activation, normal T cell expressed and secreted
(RANTES)], CCL7 (MCP3), CCL11 (eotaxin); CXC chemokines—CXCL1
[growth-regulated oncogene a (GROa)], CXCL5 [epithelial-derived
neutrophil-activating peptide 78 (ENA78)], CXCL8 (IL-8), CXCL9
[monokine induced by IFNg (MIG)], CXCL10 (IP-10); PDGF family/
VEGF subfamily—PDGFBB, VEGFA; cell adhesion molecules—
sICAM-1 [soluble intercellular adhesion molecule–1 (CD54)],
VCAM-1 [vascular cell adhesion molecule–1 (CD106)]; serine protease
inhibitor—serpin E1 (PAI1); adipose-derived hormones—leptin, resistin;
and neurotrophic/growth/cellular factors—TGFa, TGFb, FGFb (fibroblast
growth factor, basic), bNGF (b-nerve growth factor), HGF (hepatocyte
growth factor), SCF,M-CSF (CSF1), G-CSF (granulocyte colony-stimulating
factor; CSF3) (customized Procarta immunoassay, Affymetrix).
Cases (both short duration and long duration) and healthy control
subject samples were coded and run on the same assay plates in ran-
domized fashion. In addition, all plasma samples were run in duplicate
along with serial standards, buffer controls, and in-house human con-
trol plasma samples (66). Mean fluorescence intensities of analyte-
specific immunoassay bead sets were detected by flow-based Luminex
3D suspension array system (Luminex Corp.) (67). Cytokine concen-
trations were calculated by xPONENT build 4.0.846.0 and Milliplex
Analyst software (v.3.5.5.0) using a standard curve derived from the
known reference concentrations supplied by the manufacturer. A five-
parameter model was used to calculate final concentrations by inter-
polation. Values are expressed in picograms per milliliter. Concentrations
obtained below the sensitivity limit of detection (LOD) of the method7 of 10
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 were recoded to the mid-point between zero and the LOD for that
analyte for statistical comparisons. Values obtained from the reading
of samples that exceeded the upper limit of the sensitivity method
were further diluted, and cytokine concentrations were calculated
accordingly.
Statistical analysis
Descriptive statistics. Descriptive statistics were computed for
demographic variables across diagnostic groups. Sex and age were in-
cluded as possible confounders. Differences across diagnostic groups
and subgroups in proportion of females and males, sex, race, clinic
site, and months of sample acquisition were assessed by c2. Differ-
ences in median age, illness duration, and MFI mental fatigue subscale
scores were examined using the nonparametric Mann-Whitney U
(two-group comparisons) and Kruskal-Wallis (three-group compari-
sons) test.
Data transformations. Because distributions deviated from nor-





; if l ≠ 0;





where, for each cytokine variable, the optimal l was identified to
maximize the log-likelihood function (68). After transformation, all
variables failed to reject the null hypothesis using the Kolmogorov-
Smirnov test at the 0.05 level, confirming at the 95% confidence level
that all transformed variables followed a normal distribution.
GLM, t tests, and correlations. GLM analyses were applied to ex-
amine both the main effect of diagnosis and the main and interaction
effects of different fixed factors including diagnosis (two-level case
versus control comparisons and three-level short duration versus long
duration versus control analyses) and sex, with age adjusted as a con-
tinuous covariate. Because GLM uses the family-wise error rate, no
additional adjustments for multiple comparisons were applied. When
the main effect of diagnosis [one-way analysis of variance (ANOVA)/
GLM or more complex models] or the interaction term of diagnosis*sex
was found to be significant (a = 0.05), two-sample t tests, also using
a nominal a level of 0.05, were conducted to compare the mean
plasma levels of each transformed cytokine between appropriate di-
agnostic groups: cases versus controls, short-duration cases versus
controls, long-duration cases versus controls, and short-duration
versus long-duration cases. Spearman correlations were performed
to determine the relationship between the level of each cytokine
(nontransformed values, in pg/ml) and duration of illness (in years).
Logistic regression modeling. Data for the 51-plex cytokine as-
says as a whole were also used to develop a logistic regression model
for prediction of the binary response variable (case versus control,
short versus long disease duration). To eliminate multicollinearity
among cytokines, a number of dimensionality reduction methods
were used to guide selection of variables for the final logistic regression
model. Multiple methods were used to enable capture of factors po-
tentially missed by one individual method. Raw cytokine levels were
used in these analyses to allow for computation of ORs.
Dimensionality reduction methods. Feature selection strategies
select subsets of relevant features for use in regression model construc-
tion based on the assumption that the data contain many redundantHornig et al. Sci. Adv. 2015;1:e1400121 27 February 2015or irrelevant features. Feature extraction transforms highly dimension-
al input data into a reduced, representative set of features by extracting
as much relevant information as possible from the input data. We
used one of the most widely used feature selection techniques, LASSO
(69), and two feature extraction approaches, PCA and the PLS meth-
od. Details of the LASSO, PCA, and PLS methods for selection of cy-
tokine variables for inclusion in logistic regression models are described
in Supplementary Methods. A nominal a level of 0.05 defined signifi-
cance at each step of the PCA and PLS feature extraction procedures.
For LASSO, features were selected for inclusion in the model if they
were associated with a nonzero coefficient.
For the final logistic regression model, a cytokine variable was
entered either if it was selected by LASSO or if it met criteria for rep-
resenting a potential candidate via both the PCA and PLS feature
extraction methods. The ORs, their 95% CIs, and P values of the
selected cytokines were calculated accordingly.
NodeXL diagrams. The NodeXL platform was used to produce a
network diagram of 51-plex assays within each subgroup (70). The
platform provides a display of the relationships among the analytes,
thereby facilitating discovery of different cytokine-cytokine structures
across the different group populations. Bivariate Pearson’s correlations
were first conducted between every pairwise combination of cytokine
variables using their power-transformed (Box-Cox) values. We then
used the Benjamini and Hochberg method to adjust for multiple com-
parisons with a 0.01 family-wise FDR (71). Significantly correlated cy-
tokine pairs were fed into the algorithm in NodeXL to produce the
network diagram. Cytokines are represented by the “nodes” in the di-
agram, and significantly correlated cytokines are connected by “lines”
or edges. Red lines represent negative correlations; gray lines represent
positive correlations.
CART analyses. The CART (72) method was used to analyze dif-
ferences among diagnostic subgroups (short-duration ME/CFS,
long-duration ME/CFS, and controls) by examining data from 51-
plex cytokine assays from another perspective. CART is a nonparametric
decision tree learning technique that produces a classification tree for
dependent variables. It works by recursively splitting the feature space
(the values of all the independent variables, or “features,” included in
the CART analysis) into a set of nonoverlapping regions and then pre-
dicting the most likely value of the dependent variable within each
region. The decision rule at each node of the tree is determined by
searching over all independent variables and all possible values of
those independent variables to provide the split that will best differen-
tiate observations on the basis of the dependent variable (here, diag-
nostic subgroups of short-duration ME/CFS, long-duration ME/CFS,
and controls). Once a rule is selected and splits each node into two,
the same process is applied to each subsequent “child” node in the
classification tree. Partitioning stops when CART detects that there
is no further gain to be made: when diagnostic subgroups can be best
distinguished by the criterion values associated with specific variables.
To maximize predictive accuracy, the tree is pruned to optimize cross-
validation. This is accomplished by repetitively resampling two subsets
from the overall population, establishing one subset as a training set
and allowing the other subset to function as a test set. This resampling
procedure is repeated 100 times; the final tree that is selected is
based on the algorithm that best fits the data for the population in the
test set.
Statistical analyses were run in SPSS version 22.0.0.0, MATLAB
version R2013a, and R version 3.0.2.8 of 10
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